A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (NCT03930953)

🧪 Interventions in This Study

• CC-99282 (DRUG)
• Rituximab (DRUG)
• Obinutuzumab (DRUG)
• Tafasitamab (DRUG)
• Valemetostat (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (66 Sites)

Showing the first 25 of 66 sites.

• Local Institution - 109 — Scottsdale, Arizona
• Local Institution - 111 — Jacksonville, Florida
• Local Institution - 102 — Tampa, Florida
• Local Institution - 108 — Overland Park, Kansas
• Local Institution - 107 — Rochester, Minnesota
• Local Institution - 104 — St Louis, Missouri
• Local Institution - 103 — Hackensack, New Jersey
• Local Institution - 101 — Houston, Texas
• Local Institution - 255 — Ciudad Autonoma de Buenos Aires, Buenos Aires
• Local Institution - 254 — Pilar, Buenos Aires
• Local Institution - 253 — Buenos Aires,
• Local Institution - 701 — Salzburg,
• Local Institution - 704 — Sankt Pölten,
• Local Institution - 703 — Vienna,
• Local Institution - 902 — Leuven,
• Local Institution - 453 — Porto Alegre, Rio Grande do Sul
• Local Institution - 450 — São Paulo, São Paulo
• Local Institution - 451 — São Paulo,
• Local Institution - 452 — São Paulo,
• Local Institution - 201 — Toronto, Ontario
• Local Institution - 354 — Santiago, Metropolitana de Santiago
• Local Institution - 350 — Santiago, RM
• Local Institution - 355 — Recoleta, Santiago Metropolitan
• Local Institution - 353 — Santiago, Santiago Metropolitan
• Local Institution - 352 — Santiago, Santiago Metropolitan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma, Non-Hodgkin

• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Denver, Colorado
• A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Duarte, California
• A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) — Santa Monica, California
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Duarte, California
• Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma — St Louis, Missouri
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — Pasadena, California

Explore by condition: All Lymphoma, Non-Hodgkin clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.